Inferra AIResearch Tools

Inferra AI / Company / INSM

Insmed

INSM · Health Care

Last earnings Oct 29, 2026

Key results

Update Total Company revenuequarter

$524.4 Million

Business Update Total Company Revenues of $524.4 Million for the Third Quarter of 2026 BRINSUPRI (brensocatib)

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenuequarter

$400.1 Million

Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026 ARIKAYCE (amikacin liposome inhalation suspension)

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

1 ARIKAYCE ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

$ 473.6 $ 102.0 364% $ 1,122.4 $ 235.0 378% International 50.8 40.3 26% 133.5 107.6 24% Total $ 524.4 $ 142.3 268% $ 1,255.9 $ 342.6 267% Cost of product revenues (excluding amortization of intangibles) were $78.2 million for the third quarter of 2026, compared to $29.4 million for the third quarter of 2025.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Launch Analog Footnotes (2 of 3) DUPIXENT | Launched in Q2 2017 Dupixent collaboration revenue was US$28.6 million during the second quarter of 2017 (Regeneron Pharmaceuticals, Inc.

SEC original ↗Insmed — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2026

htm Dupixent collaboration revenue was US$89 million in the third quarter of 2017, with sales occurring almost exclusively in the United States (Regeneron Pharmaceuticals, Inc.

SEC original ↗Insmed — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2026

AI analysis

Q3 2026 · reported Oct 29, 2026

Based on: Earnings release + Q3 2026 deck + parent 8-K + 10-Q — transcript not held

Revenue · Q3 2026
$400.1M
EX-99 · Oct 29, 2026
Update Total Company revenue · Q3 2026
$524.4M
EX-99 · Oct 29, 2026

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Oct 29, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2026Prior qtrYear ago
Update Total Company revenue$524.4 Million——
Revenue$400.1 Million——

EX-99 · Oct 29, 2026

Guidance · company-stated

Direction: Raised

Revenue

“4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025 Company Raises 2026 BRINSUPRI Revenue Guidance to $1.”

Revenue$460 Million

“4 Billion Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan BRIDGEWATER, N.”

Revenue

“The Company raised its full-year 2026 revenue guidance for BRINSUPRI to a range of $1.”

Revenue

“The Company raised its full-year 2026 revenue guidance for ARIKAYCE to a range of $460 million to $470 million from the previous guidance of $450 million to $470 million.”

Midpoint vs latest-quarter revenue+15.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest.

Secured Senior Term Loan The carrying value of the Company's secured senior term loans are measured at amortized cost using the effective interest method and the carrying value approximates fair value.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue +15.0% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Insmed Q3 2026 — Business Update Total Company Revenues of $524.4 Million for the Third Quarter of 2026 BRINSUPRI (brensocatib)

Based on: Earnings release + Q3 2026 deck + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025 Company Raises 2026 BRINSUPRI Revenue Guidance to $1.”

Revenue: “4 Billion Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan BRIDGEWATER, N.”

Revenue: “The Company raised its full-year 2026 revenue guidance for BRINSUPRI to a range of $1.”

Revenue: “The Company raised its full-year 2026 revenue guidance for ARIKAYCE to a range of $460 million to $470 million from the previous guidance of $450 million to $470 million.”

Revenue — Raised (“Raises”)
“4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025 Company Raises 2026 BRINSUPRI Revenue Guidance to $1.”

Revenue — Raised (“Raises”)
“4 Billion Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan BRIDGEWATER, N.”

Revenue — Raised (“raise”)
“This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.”

Revenue — Raised (“raised”)
“The Company raised its full-year 2026 revenue guidance for BRINSUPRI to a range of $1.”

Revenue — Raised (“raised”)
“The Company raised its full-year 2026 revenue guidance for ARIKAYCE to a range of $460 million to $470 million from the previous guidance of $450 million to $470 million.”

Classified from the release's primary full-year outlook statement.

Capital allocation

This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest.

SEC original ↗Insmed — 10-Q Quarterly report10-QOct 29, 2026

Secured Senior Term Loan The carrying value of the Company's secured senior term loans are measured at amortized cost using the effective interest method and the carrying value approximates fair value.

SEC original ↗Insmed — 10-Q Quarterly report10-QOct 29, 2026

See Note 10 - Debt for further details .

SEC original ↗Insmed — 10-Q Quarterly report10-QOct 29, 2026

Debt Amended and Restated Loan Agreement In October 2022, the Company entered into the $ 350.0 million loan agreement (the Loan Agreement) with Pharmakon Advisors LP (Pharmakon) that would have matured on October 19, 2027 (the Tranche A Term Loan).

SEC original ↗Insmed — 10-Q Quarterly report10-QOct 29, 2026

The Tranche A Term Loan originally bore interest at a rate based upon the Secured Overnight Financing Rate (SOFR) , subject to a SOFR floor of 2.5 %, in addition to a margin of 7.75 % per annum.

SEC original ↗Insmed — 10-Q Quarterly report10-QOct 29, 2026

Up to 50 % of the interes t payable during the first 24 months from the closing of the Tranche A Term Loan could have been paid-in-kind at the Company's election.

SEC original ↗Insmed — 10-Q Quarterly report10-QOct 29, 2026

Strategy & priorities

As we advance our Phase 3 TPIP programs across four large indications and progress our early-stage pipeline, we remain focused on delivering meaningful innovation and improving the lives of patients with serious diseases.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The FDA granted Priority Review to the sNDA and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Insmed plans to submit data from the Phase 3 ENCORE study to Japan s Pharmaceuticals and Medical Devices Agency (PMDA) in the fourth quarter of 2026 to support potential ARIKAYCE label expansion to all patients with MAC lung disease.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

and label expansion to include all patients with MAC lung disease in the U.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines including two approved therapies to treat chronic, debilitating lung diseases as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Risks & headwinds

12 Forward-looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The forward-looking statements in this press release are based upon the Company s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Such risks, uncertainties and other factors include, among others, the following: failure to continue to successfully commercialize ARIKAYCE in the U.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

13 The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, Risk Factors, in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission (SEC).

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

htm EXHIBIT 99.2 Exhibit 99.2 October 29, 2026 Third-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements.

SEC original ↗Insmed — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2026

What changed vs prior quarter

Update Total Company revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Insmed — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Documents

Earnings deck slides

0 decks with slide view

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Insmed — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

37 documents

Earnings releases

13 documents

Presentations

7 documents

Transcripts

0 documents

No transcripts for Insmed are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention Insmed by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.